key: cord-0759366-to1n9wkd
authors: GOUEL-CHERON, Aurélie; ELMALEH, Yoann; COUFFIGNAL, Camille; KANTOR, Elie; MESLIN, Simon; CAILLARD, Anaïs; SALOME, Arthur; HAMADA, Sophie; CHOLLEY, Bernard; MEBAZAA, Alexandre; LONGROIS, Dan; Jean-Louis, B.O.U.R.G.A.I.N.; BILLARD, Valérie; SERVIN, Frédérique; MONTRAVERS, Philippe
title: Effectiveness of anaesthesia ventilator use for mechanical ventilation in critically ill patients during the COVID-19 pandemic
date: 2021-04-12
journal: Br J Anaesth
DOI: 10.1016/j.bja.2021.04.001
sha: 603093df86090ffa6ce84702575e0632e9a1146e
doc_id: 759366
cord_uid: to1n9wkd

nan

Effectiveness of anaesthesia ventilator use for mechanical ventilation in critically ill patients 1 during the COVID-19 pandemic 2 Short running title: Ventilation strategy during pandemics 3

Aurélie GOUEL-CHERON 1,2,3,4,* , Yoann ELMALEH 1 , Camille COUFFIGNAL 5,6 , Elie 4 KANTOR 1, 4 , Simon MESLIN 7 , Anaïs CAILLARD 8 , Arthur SALOME 11 , Sophie HAMADA 7 , 5 Bernard CHOLLEY 7 , Alexandre MEBAZAA 4,8, 9 , Dan LONGROIS 1, 4, 9, 10 , Jean-Louis 6 BOURGAIN 11 , Valérie BILLARD 11 , Frédérique SERVIN 1,4 , Philippe MONTRAVERS 1,4,12 7 8

1 -Anaesthesiology and Critical Care Medicine Department, DMU PARABOL, Bichat 9 Hospital, AP-HP, Paris of the most important settings is fresh gas flow, which has to be  150% of the patient's 7 minute ventilation. The literature on this subject was virtually nonexistent. 8

This was a retrospective, multicentre, observational cohort analysis with prospectively 9

collected data to evaluate the effectiveness of IMV in ICU patients with anaesthesia 10 ventilators in adherence with STROBE guidelines 5 . The primary objective was to evaluate 11 feasibility of use of anaesthesia ventilators for prolonged IMV in ICU patients, tracking 12 ventilation failure within 72 h after IMV initiation, defined as any change in the type of 13 ventilator used (except for logistic purposes). The secondary objective was to report specific 14 management of these medical devices through condensation of water in the breathing circuit 15 and ventilator as measured by the frequency of filter changes and water trap emptying. 16 Study design was described in a preliminary report 6 . Ethics committee approval was obtained 17 by the French Pneumology Society (CEPRO 2020-017). All adult patients admitted to one of 18 the five Parisian university hospital study centres who required IMV for more than 24 h, 19 regardless of whether they had COVID-19, were included if an anaesthesia ventilator was 20 used at the beginning of IMV because of a shortage of ICU ventilators. Data collection and 21

handling are described in the Supplemental data. Data included patient characteristics, 22 COVID-19 status, medical information, ventilation characteristics, ICU-specific care, 23 outcome and arterial blood gas analysis at 72 h after ICU admission. A descriptive analysis 24 was performed using R ® software (give URL here; medians and interquartile ranges, 25 frequencies and percentages when applicable, with calculation of 95% confidence intervals). 26

From March 21 to April 13, 2020, 50 patients were enrolled (Table 1 and Supplemental Table  27 1), and 41 patients (82%) had COVID-19 at baseline and 47 patients (94%) were admitted to 28 ICU for respiratory distress. Every patient was managed using ventilation control mode 29 (supplemental Table 2 ). Six patients required a switch from an anaesthesia ventilator to an 30 ICU ventilator within the first 72 h of IMV. Three patients were transferred to another French 31 region in which the pandemic was less widespread. One was transferred to a regular ICU 32 when a bed became available (four switches considered "logistical"). Thanks to a 6-fold decrease in surgeries, equipment (anaesthesia ventilators) and staff (nurses 48 and anaesthesiologists, with dual ability in anaesthesiology and intensive care) were 49 reallocated to regular and temporary ICUs, allowing coverage by trained physicians with 1 intensive care experience. 9a Care was provided with the same protocols and the highest 2 possible quality, regardless of which type of unit the patients were hospitalized in. In clinical 3 practice, the recommendation is to change HME filters after every anaesthesia procedure 9 , 4 although their efficacy has been the subject of controversy, especially in condensation and 5 high pressure conditions. For pneumonia prevention in mechanically-ventilated ICU patients, 6

the recommendation is to change the HME when it mechanically malfunctions or becomes 7 visibly soiled. We assume that the same strategy should be used during prolonged IMV with 8 an anaesthesia ventilators. 9

Our study has several limitations, such as potential bias induced by the definition of logistical 10 reasons for changes in ventilators and the retrospective aspects (which prevented us from 11

collecting additional data such as lung compliance). Also, the 72-h duration may not be 12 sufficient to evaluate the safety and effectiveness of this strategy; that timeframe was selected 13 as a compromise between study feasibility and evaluation quality. We were not able to assess 14 the impact of anaesthesia ventilator use on outcomes or gas exchange, as this was not the 15 purpose of our study. 

Clinical course and mortality risk of severe COVID-19. The 2 Lancet Elsevier

A national healthcare response to intensive 4 care bed requirements during the COVID-19 outbreak in France

A Framework for Rationing Ventilators and Critical Care Beds During 8 the COVID-19 Pandemic

Préconisations pour la ventilation en réanimation de patients COVID avec des 10 ventilateurs d'anesthésie

Société Française d'Anesthésie et de 11 Réanimation

The Strengthening the Reporting of 14 Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting 15 Observational Studies

Preliminary 17 observations of anaesthesia ventilators use for prolonged mechanical ventilation in 18 intensive care unit patients during the COVID-19 pandemic

Surviving Sepsis Campaign: Guidelines on 21 the Management of Critically Ill Adults with Coronavirus Disease

COVID-19 pneumonia: different respiratory 1 treatments for different phenotypes?